Nolpaza Enteric Tablets 20mg: Relieve Heartburn and Acid Reflux Symptoms
Get relief from the discomfort of heartburn and acid reflux with Nolpaza enteric tablets 20mg. This medication effectively reduces stomach acid production, providing long-lasting relief and helping to prevent future episodes.
Key Features:
- Fast-Acting Relief: Nolpaza works quickly to reduce acid production, offering relief from heartburn and acid reflux symptoms within hours.
- Long-Lasting Effects: Its enteric coating ensures delayed release in the intestines, providing prolonged symptom management.
- Easy to Use: Simply swallow one tablet whole with water before meals.
- Available in Convenient Packaging: Nolpaza is available in blister packs of 14 tablets, making it easy to manage your treatment.
Who is Nolpaza for?
Nolpaza is suitable for adults and adolescents 12 years and older experiencing:
- Symptomatic Gastroesophageal Reflux Disease (GERD): This medication is effective in treating and preventing the return of GERD symptoms.
- Reflux Esophagitis: Nolpaza helps heal the inflammation and damage caused by acid reflux.
- Long-Term Maintenance Therapy: It can help prevent the recurrence of GERD symptoms after initial relief.
Important Information:
- Consult your doctor before taking Nolpaza.
- Do not use Nolpaza if you are allergic to pantoprazole or other benzimidazoles.
- Inform your doctor about any existing medical conditions or medications you are taking.
- Nolpaza may interact with other medications, including blood thinners and certain antifungal drugs.
Nolpaza is a prescription medication. Speak to your doctor to determine if it’s right for you and to discuss any potential side effects or drug interactions.
Buy Nolpaza Enteric Tablets 20mg №14×2 today and experience relief from heartburn and acid reflux symptoms.
Disclaimer: This information is for general knowledge and informational purposes only, and does not constitute medical advice. It is essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
| INN | PANTOPRAZOLE |
|---|---|
| The code | 46 075 |
| Side effects | Uncommon (≥ 1/1, 000 to <1/100) sleep disturbances headache, dizziness diarrhea, nausea, vomiting, bloating and flatulence, constipation, dry mouth, abdominal pain, discomfort elevated liver enzymes (transaminases, γ-GT) rash, exanthema, skin rash, itching fractures of the bones of the spine, hip and wrist asthenia, malaise and fatigue Rarely (from ≥ 1/10, 000 to <1/1, 000) agranulocytosis hypersensitivity reactions (including anaphylactic reactions and anaphylactic shock) hyperlipidemia, increased levels of triglycerides, cholesterol, changes in body weight, taste disturbance depression (and all exacerbations) visual disturbances, blurred vision increased bilirubin levels urticaria, Quincke's edema arthralgia, myalgia gynecomastia fever, peripheral edema Very rarely (<1/ 10, 000) thrombocytopenia, leukopenia, confusion (and all associated exacerbations) Not known (cannot be estimated from the available data): hyponatremia, hypomagnesemia hallucinations inations, confusion (especially in genetically predisposed patients, and exacerbation of these symptoms if they existed before treatment) hepatocellular damage, jaundice, hepatocellular insufficiency Stevens-Johnson syndrome, Lyell's syndrome, erythema multiforme, photosensitivity interstitial nephritis |
| Importer | IOOO Interfarmaks 223028 Minsk region, Minsk district, Zhdanovichsky s / s, ag. Zhdanovichi, st. Star, 19a-5, room. 5-2 |
| Composition Means | active substance – pantoprazole sodium sesquihydrate 22.55 mg or 45.10 mg (equivalent to pantoprazole 20 mg or 40 mg, respectively), excipients: mannitol, crospovidone (type B), anhydrous sodium carbonate, sorbitol (E420), calcium stearate, composition enteric coating: hypromellose (2.4-3.6 mPas), povidone (K25), titanium dioxide (E171), iron oxide yellow (E172), propylene glycol, *methacrylic acid-ethyl acrylate copolymer (1:1) 30% dispersion, macrogol 6000, talc |
| Main Active Substances | pantoprazole sodium sesquihydrate 22.55 mg or 45.10 mg |
| Release Form | tablets |
| Application Gender | Any |
| Use during pregnancy and lactation | unknown |
| Contraindications | hypersensitivity to pantoprazole, substituted benzimidazoles or auxiliary components of the drug – combined use with atazanavir |
| Barcode | 3, 84E+12 |
| Indications Applications | For a dosage of 20 mg: Adults and adolescents from 12 years of age and older – symptomatic gastroesophageal reflux disease – for the long-term treatment and prevention of relapse of reflux esophagitis. Adults – prevention of erosive and ulcerative lesions of the stomach and duodenum caused by the use of non-selective non-steroidal anti-inflammatory drugs (NSAIDs) in patients at increased risk and in need of ongoing treatment with NSAIDs (See section "special instructions") For a dosage of 40 mg Adults and adolescents from 12 years and older – reflux esophagitis Adults – eradication of Helicobacter pylori (H. pylori) in combination with appropriate antibiotic therapy in patients with peptic ulcer associated with H. pylori – peptic ulcer of the stomach and duodenum – Zollinger-Ellison syndrome and other pathological hypersecretory states |
| trade line | Nolpaza |
| Trademark | KRKA |
| Manufacturer | Krka dd, Slovenia |
| Active substance | Pantoprazole |
| Dosage | 20mg |
Related products
